Cargando…

Protective efficacy of statins in patients with Klebsiella pneumoniae bloodstream infection

BACKGROUND: Patients with bloodstream infection of Klebsiella pneumoniae (BSI-KP) have a high risk of death and septic shock. This study aims to identify the risk factors for mortality and severity in patients of BSI-KP. METHODS: Data of BSI-KP patients were extracted from the MIMIC IV (Medical Info...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Qian, Zheng, Beiwen, Shen, Ping, Xiao, Yonghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849249/
https://www.ncbi.nlm.nih.gov/pubmed/36683706
http://dx.doi.org/10.3389/fcimb.2022.1087701
_version_ 1784871910610305024
author Xu, Qian
Zheng, Beiwen
Shen, Ping
Xiao, Yonghong
author_facet Xu, Qian
Zheng, Beiwen
Shen, Ping
Xiao, Yonghong
author_sort Xu, Qian
collection PubMed
description BACKGROUND: Patients with bloodstream infection of Klebsiella pneumoniae (BSI-KP) have a high risk of death and septic shock. This study aims to identify the risk factors for mortality and severity in patients of BSI-KP. METHODS: Data of BSI-KP patients were extracted from the MIMIC IV (Medical Information Mart for Intensive Care IV) database, and patients infected with only K. pneumoniae in blood were included in this study. The risk factors of 28-day mortality and septic shock in BSI-KP patients were analyzed, respectively. RESULTS: A total of 279 patients enrolled and the all-cause 28-day mortality rate was 11.8%. The use of statins (OR 0.220, 95% CI 0.060-0.801, p = 0.022) and quinolones (OR 0.356, 95% CI 0.143-0.887, p = 0.027) were both independent protective factors for death within 28 days, while the use of vasoactive drugs (OR 7.377, 95% CI 1.775-30.651, p = 0.006) was a risk factor. Besides, pulmonary disease (OR 2.348, 95% CI 1.126-4.897, p = 0.023), bleeding and coagulation disorders (OR 3.626, 95% CI 1.783-7.372, p < 0.001), respiratory failure (OR 2.823, 95% CI 0.178-6.767, p = 0.020) and kidney dysfunction (OR 2.450, 95% CI 1.189-5.047, p = 0.015) were independent risk factors for patients suffered from septic shock while hypertension was a protective one. The receiver operating characteristic (ROC) curves could well predict the risk of death within 28-day (area under ROC = 0.855, 95% CI = 0.796–0.914, p < 0.001) and septic shock (AUROC = 0.815, 95% CI = 0.755–0.874, p < 0.001) in patients with BSI-KP. CONCLUSION: The use of statins could decrease the risk of 28-day mortality in patients of BSI-KP. The risk factor-based prediction model provided evidence for drug treatment in BSI-KP patients. Paying more attention to the strategy of drug treatment will be an optimal way to improve patient’s outcome in clinical practice.
format Online
Article
Text
id pubmed-9849249
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98492492023-01-20 Protective efficacy of statins in patients with Klebsiella pneumoniae bloodstream infection Xu, Qian Zheng, Beiwen Shen, Ping Xiao, Yonghong Front Cell Infect Microbiol Cellular and Infection Microbiology BACKGROUND: Patients with bloodstream infection of Klebsiella pneumoniae (BSI-KP) have a high risk of death and septic shock. This study aims to identify the risk factors for mortality and severity in patients of BSI-KP. METHODS: Data of BSI-KP patients were extracted from the MIMIC IV (Medical Information Mart for Intensive Care IV) database, and patients infected with only K. pneumoniae in blood were included in this study. The risk factors of 28-day mortality and septic shock in BSI-KP patients were analyzed, respectively. RESULTS: A total of 279 patients enrolled and the all-cause 28-day mortality rate was 11.8%. The use of statins (OR 0.220, 95% CI 0.060-0.801, p = 0.022) and quinolones (OR 0.356, 95% CI 0.143-0.887, p = 0.027) were both independent protective factors for death within 28 days, while the use of vasoactive drugs (OR 7.377, 95% CI 1.775-30.651, p = 0.006) was a risk factor. Besides, pulmonary disease (OR 2.348, 95% CI 1.126-4.897, p = 0.023), bleeding and coagulation disorders (OR 3.626, 95% CI 1.783-7.372, p < 0.001), respiratory failure (OR 2.823, 95% CI 0.178-6.767, p = 0.020) and kidney dysfunction (OR 2.450, 95% CI 1.189-5.047, p = 0.015) were independent risk factors for patients suffered from septic shock while hypertension was a protective one. The receiver operating characteristic (ROC) curves could well predict the risk of death within 28-day (area under ROC = 0.855, 95% CI = 0.796–0.914, p < 0.001) and septic shock (AUROC = 0.815, 95% CI = 0.755–0.874, p < 0.001) in patients with BSI-KP. CONCLUSION: The use of statins could decrease the risk of 28-day mortality in patients of BSI-KP. The risk factor-based prediction model provided evidence for drug treatment in BSI-KP patients. Paying more attention to the strategy of drug treatment will be an optimal way to improve patient’s outcome in clinical practice. Frontiers Media S.A. 2023-01-05 /pmc/articles/PMC9849249/ /pubmed/36683706 http://dx.doi.org/10.3389/fcimb.2022.1087701 Text en Copyright © 2023 Xu, Zheng, Shen and Xiao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Xu, Qian
Zheng, Beiwen
Shen, Ping
Xiao, Yonghong
Protective efficacy of statins in patients with Klebsiella pneumoniae bloodstream infection
title Protective efficacy of statins in patients with Klebsiella pneumoniae bloodstream infection
title_full Protective efficacy of statins in patients with Klebsiella pneumoniae bloodstream infection
title_fullStr Protective efficacy of statins in patients with Klebsiella pneumoniae bloodstream infection
title_full_unstemmed Protective efficacy of statins in patients with Klebsiella pneumoniae bloodstream infection
title_short Protective efficacy of statins in patients with Klebsiella pneumoniae bloodstream infection
title_sort protective efficacy of statins in patients with klebsiella pneumoniae bloodstream infection
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849249/
https://www.ncbi.nlm.nih.gov/pubmed/36683706
http://dx.doi.org/10.3389/fcimb.2022.1087701
work_keys_str_mv AT xuqian protectiveefficacyofstatinsinpatientswithklebsiellapneumoniaebloodstreaminfection
AT zhengbeiwen protectiveefficacyofstatinsinpatientswithklebsiellapneumoniaebloodstreaminfection
AT shenping protectiveefficacyofstatinsinpatientswithklebsiellapneumoniaebloodstreaminfection
AT xiaoyonghong protectiveefficacyofstatinsinpatientswithklebsiellapneumoniaebloodstreaminfection